[Analysis of core functional components in Yinchenhao Decoction and their pathways for treating liver fibrosis]. [PDF]
Chen X +8 more
europepmc +1 more source
[Challenges and optimization strategies for clinical research and the development of new drugs for liver fibrosis]. [PDF]
Cai XB, Qu Y, Lu LG.
europepmc +1 more source
[Inhibiting Yes-associated protein alleviates CCl4 liver fibrosis in mice by reducing epithelial mesenchymal transition]. [PDF]
Zhao W +6 more
europepmc +1 more source
[Characteristics of liver volume and pathological changes with different stages of liver fibrosis in chronic liver disease]. [PDF]
Zhu TT +7 more
europepmc +1 more source
[Long-term therapeutic outcomes of antiviral treatment in patients with chronic hepatitis B infection with normal alanine aminotransferase, mild liver inflammation, and fibrosis]. [PDF]
Shi YC, Tan YW.
europepmc +1 more source
Expression and predictive value of serum core fucosylated low molecular weight kininogen and alpha-galactosylated antibodies in patients with hepatic fibrosis. [PDF]
Zhang X +8 more
europepmc +1 more source
MiR-4465-modified mesenchymal stem cell-derived small extracellular vesicles inhibit liver fibrosis development via targeting LOXL2 expression. [PDF]
Wang Y +7 more
europepmc +1 more source
[A case of cholangitis-type congenital hepatic fibrosis due to a mutation in the polycystic kidney/hepatic disease 1 gene]. [PDF]
He JJ, Pei ZY, Zhang LY.
europepmc +1 more source

